As reported in Systems Medicine, a new study supports the use of virtual patients and in silico clinical studies to evaluate the effectiveness of blue light to reduce the symptoms of psoriasis. The research team demonstrated that this in silico approach can be used to improve the treatment response of patients with psoriasis when using blue light by modifying the settings of the therapeutic protocol.
Titled “In silico Clinical Studies on the Efficacy of Blue Light for Treating Psoriasis in Virtual Patients.” The researchers note that the current computational model for studying the efficacy of blue light therapy only reproduces the response in the average patient in clinical trials and does not consider individual variations amongst patients.
The use of a computational model combined with a refined pool of virtual patients can adequately capture the patient variability in the response to treatment with blue light, as well as capturing the decrease in disease severity seen in previous clinical investigations. The authors point out that a minimum of 2,500 virtual patients, which they refined down from an initial pool of 500,000 virtual patients, are needed to reproduce the responses seen in clinical investigations.
Zandra Félix Garza
Natal van Riel, Eindhoven University of Technology, The Netherlands
Joerg Liebmann, Philips Electronics Netherlands BV, Eindhoven
Matthias Born, Philips Electronics Netherlands BV, Eindhoven